Prognostic factors of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children: Report of the Japan Histiocytosis Study Group

Pediatric Blood and Cancer

Volumn 61, Issue 7, 2014, Pages 1257-1262

  Kogawa, Kazuhiro ^a,b   Sato, Hiroki ^c   Asano, Takeshi ^b   Ohga, Shouichi ^b   Kudo, Kazuko ^b   Morimoto, Akira ^b   Ohta, Shigeru ^b   Wakiguchi, Hiroshi ^b   Kanegane, Hirokazu ^d   Oda, Megumi ^d   Ishii, Eiichi ^b  

^a Tsuchiya Children's Hospital   (Japan)

^b HLH LCH Committees in the Japanese Society of Pediatric Hematology   (Japan)

^c NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^d Research Education Committees in the Japanese Society of Pediatric Infectious Diseases   (Japan)

Author keywords

Epstein Barr virus; Epstein Barr virus associated hemophagocytic lymphohistiocytosis; Hyperbilirubinemia; Hyperferritinemia

Indexed keywords

BILIRUBIN; CORTICOSTEROID; CYCLOSPORIN; ETOPOSIDE; FERRITIN;

ACUTE MONOCYTIC LEUKEMIA; ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; BONE MARROW; CAUSE OF DEATH; CLINICAL FEATURE; CLONAL VARIATION; CORTICOSTEROID THERAPY; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS ASSOCIATED HEMOPHAGOCYTIC SYNDROME; EPSTEIN BARR VIRUS INFECTION; ERYTHROPHAGOCYTOSIS; FEMALE; FERRITIN BLOOD LEVEL; FEVER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOPHAGOCYTIC SYNDROME; HEPATOMEGALY; HEPATOSPLENOMEGALY; HUMAN; HYPERBILIRUBINEMIA; HYPERFERRITINEMIA; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; JAPAN; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; NEUROLOGIC DISEASE; NEUTROPHIL COUNT; ONSET AGE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARTIAL THROMBOPLASTIN TIME; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RECURRENT VIRUS INFECTION; REMISSION; SPLENOMEGALY; SURVIVAL RATE; TREATMENT RESPONSE; VIRUS LOAD;

EPSTEIN-BARR VIRUS; EPSTEIN-BARR VIRUS-ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HYPERBILIRUBINEMIA; HYPERFERRITINEMIA;

ADRENAL CORTEX HORMONES; AGE OF ONSET; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ASIAN CONTINENTAL ANCESTRY GROUP; BILIRUBIN; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; DATA COLLECTION; DISEASE-FREE SURVIVAL; EPSTEIN-BARR VIRUS INFECTIONS; ETOPOSIDE; HERPESVIRUS 4, HUMAN; HUMANS; HYPERBILIRUBINEMIA; IMMUNOSUPPRESSIVE AGENTS; INFANT; JAPAN; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84899682435     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24980     Document Type: Article

References (29)

1. Loy TS, Diaz-Arias AA, Perry MC. Familial erythrophagocytic lymphohistiocytosis. Semin Oncol 1991; 18:34-38.
2. Imashuku S, Teramura T, Tauchi H, et al. Longitudinal follow-up of patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Haematologica 2004; 89:183-188.
3. Henter JI, Ehrnst A, Anderson J, et al. Familial hemophagocytic lymphohistiocytosis and viral infection. Acta Paediatr 1993; 82:369-372.
4. Janka G, Imashuku S, Elinder G, et al. Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am 1998; 12:435-444.
5. Ishii E, Ohga S, Imashuku S, et al. Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int J Hematol 2007; 86:58-65.
6. Kawaguchi H, Miyashita T, Herbst H, et al. Epstein-Barr virus-infected T lymphocytes in Epstein-Barr virus-associated hemophagocytic syndrome. J Clin Invest 1993; 92:1444-1450.
7. Imashuku S, Hibi S, Todo S. Hemophagocytic lymphohistiocytosis in infancy and childhood. J Pediatr 1997; 130:352-357.
8. Imashuku S, Kuriyama K, Teramura T, et al. Requirement for etoposide in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Clin Oncol 2001; 19:2665-2673.
9. Imashuku S, Hibi S, Ohara T, et al. Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Blood 1999; 93:1869-1874.
10. Imashuku I, Teramura T, Kuriyama K, et al. Risk of etoposide-related acute myeloid leukemia in the treatment of Epstein Barr virus-associated hemophagocytic lymphohistiocytosis. Int J Hematol 2002; 75:174-177.
11. Kimura H, Morita M, Yabuta Y, et al. Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. J Clin Microbiol 1999; 37:132-136.
12. Kasahara Y, Yachie A, Takei K, et al. Differential cellular targets of Epstein-Barr virus (EBV) infection between acute EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Blood 2001; 98:1882-1888.
13. Imashuku S, Hibi S, Tabata Y, et al. Outcome of clonal hemophagocytic lymphohistiocytosis: Analysis of 32 cases. Leuk Lymphoma 2000; 37:577-584.
14. Henter JI, Horne A, Aricó M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Ped Blood Cancer 2007; 48:128-131.
15. Imashuku S, Ikushima S, Hibi S, et al. Langerhans cell histiocytosis and hemophagocytic syndrome in Japan: Epidemiological studies. Int J Pediatr Hematol/Oncol 1994; 1:241-246.
16. Su IJ, Wang CH, Cheng AL, et al. Hemophagocytic syndrome in Epstein-Barr virus-associated T-lymphoproliferative disorders: Disease spectrum, pathogenesis, and management. Leuk Lymphoma 1995; 19:401-406.
17. Moss DJ, Burrows SR, Khanna R, et al. Immune surveillance against Epstein-Barr virus. Semin Immunol 1992; 4:97-104.
18. Larroche C, Mouthon L. Pathogenesis of hemophagocytic syndrome (HPS). Autoimmun Rev 2004; 3:69-75.
19. Kasahara Y, Yachie A. Cell type specific infection of Epstein-Barr virus (EBV) in EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Crit Rev Oncol Hematol 2002; 44:283-294.
20. Nazaruk RA, Rochford R, Hobbs MV, et al. Functional diversity of the CD8 (+) T-cell response to Epstein-Barr virus (EBV): Implications for the pathogenesis of EBV-associated lymphoproliferative disorders. Blood 1998; 91:3875-3883.
21. Hatta K, Morimoto A, Ishii E, et al. Association of transforming growth factor-beta1 gene polymorphism in the development of Epstein-Barr virus related hematologic diseases. Haematologica 2007; 92:1470-1474.
22. Matsuda K, Nakazawa Y, Yanagisawa R, et al. Detection of T-cell receptor gene rearrangement in children with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis using the IOMED-2 multiplex polymerase chain reaction combined with GeneScan analysis. Clin Chim Acta 2011; 412:1554-1558.
23. Trottestam H, Berglöf E, Horne A, et al. Risk factors for early death in children with hemophagocytic lymphohistiocytosis. Acta Paediatr 2012; 101:313-318.
24. Huang SC, Chen JS, Cheng CN, et al. Hypoalbuminaemia is an independent predictor for hemophagocytic lymphohistiocytosis. Eur J Haematol 2012; 89:417-422.
25. Ohga S, Kudo K, Ishii E, et al. Hematopoietic stem cell transplantation for familial hemophagocytic lymphohistiocytosis and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Japan. Pediatr Blood Cancer 2010; 54:299-306.
26. Qin Q, Xie Z, Shen Y, et al. Assessment of immunochemotherapy and stem cell transplantation on EBV-associated hemophagocytic lymphohistiocytosis in children: A systematic review and meta analysis. Eur Rev Med Pharmacol Sci 2012; 16:672-678.
27. Balamuth NJ, Nichols KE, Paessler M, et al. Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein Barr virus-associated hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol 2007; 29:569-573.
28. Milone MC, Tsai DE, Hodinka RL, et al. Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy. Blood 2005; 105:994-996.
29. Mahlaoui N, Ouachée-Chardin M, de Saint Basile, G, et al. Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: A single-center retrospective report of 38 patients. Pediatrics 2007; 120:622-628.